Neuroendocrine Tumors / NETs (Nutritional Support)
Diverse hormone-secreting tumors of the digestive tract, lungs, and pancreas requiring specialized dietary management of carcinoid syndrome, hormone excess, and targeted therapy support
Overview
Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies arising from neuroendocrine cells throughout the body — most commonly in the gastrointestinal tract (small intestine, rectum, appendix, colon), pancreas (pNETs), and lungs (~bronchial carcinoids). Incidence has risen 6-fold over the past 40 years (~12,000 new cases/year in the US; ~170,000 prevalent cases). NETs are classified by grade (G1: Ki-67 <3%, G2: Ki-67 3–20%, G3: Ki-67 >20%) and functional status (functional NETs secrete hormones causing clinical syndromes; non-functional NETs are more common). Functional syndromes: carcinoid syndrome (serotonin excess — flushing, diarrhea, wheezing, carcinoid heart disease), insulinoma (hypoglycemia), gastrinoma/Zollinger-Ellison syndrome (peptic ulcers, diarrhea), VIPoma (watery diarrhea, hypokalemia), glucagonoma (diabetes, necrolytic migratory erythema). Five-year survival: ~83% (localized), ~62% (regional), ~26% (distant). Treatments: surgery (curative for localized disease), somatostatin analogues (octreotide LAR, lanreotide — PROMID and CLARINET trials; control hormone symptoms and slow tumor growth), everolimus (mTOR inhibitor — RADIANT trials), sunitinib (pNETs — SUN1111 trial), peptide receptor radionuclide therapy (PRRT — lutetium-177 dotatate/Lutathera, FDA approved 2018 — NETTER-1 trial: 79% PFS benefit), telotristat ethyl (tryptophan hydroxylase inhibitor — reduces serotonin synthesis; FDA approved 2017 for carcinoid syndrome diarrhea). 2025–2026 advances: NETTER-2 trial (2024) — lutetium-177 dotatate first-line for high-uptake G2/G3 NETs: improved PFS (22.8 vs 8.5 months; HR 0.276) vs high-dose octreotide LAR; expanding PRRT to earlier lines of therapy and higher-grade NETs; lutetium-177 dotatate + everolimus combination (COMPETE trial: 20.1-month PFS vs 12.0 months with everolimus alone); surufatinib (VEGFR/FGFR1/CSF1R inhibitor) — Phase III SANET-ep and SANET-p trials showing activity in extra-pancreatic and pancreatic NETs; NDA submitted to FDA; cabozantinib for pNETs and extra-pancreatic NETs (CABINET trial: 8.5-month PFS vs 3.2 months placebo in pNETs; 5.6-month PFS vs 3.4 months in extra-pancreatic NETs — FDA approved 2024 for NETs); pembrolizumab for high-grade NEC (neuroendocrine carcinoma, Ki-67 >20%); olutasidenib for IDH1-mutant NETs; actinium-225 dotatate (alpha-emitter PRRT) in Phase I/II — more potent than lutetium-177 with shorter range; copper-64/67 dotatate for theranostics; belzutifan for VHL-associated pNETs (FDA approved 2021 for VHL disease); selpercatinib for RET-mutant pNETs (MEN2 syndrome); comprehensive molecular profiling (DAXX/ATRX, MEN1, VHL, RET, SDHB, TSC1/2) now recommended for all advanced pNETs. Nutritional rationale: carcinoid syndrome causes severe diarrhea and malabsorption of fat, protein, and fat-soluble vitamins; serotonin excess depletes tryptophan (niacin precursor) causing pellagra-like niacin deficiency; octreotide causes fat malabsorption and gallstone formation; everolimus causes hyperglycemia and mucositis; PRRT requires adequate renal function and amino acid infusion for kidney protection.
Evidence highlight: NETTER-2 trial (2024): lutetium-177 dotatate first-line PFS 22.8 vs 8.5 months (HR 0.276) vs high-dose octreotide LAR in G2/G3 NETs (Singh et al., 2024). CABINET trial (2024): cabozantinib FDA approved for NETs — pNETs PFS 8.5 vs 3.2 months; extra-pancreatic NETs PFS 5.6 vs 3.4 months. COMPETE trial: lutetium-177 dotatate + everolimus PFS 20.1 vs 12.0 months vs everolimus alone. NETTER-1: lutetium-177 dotatate reduced disease progression/death by 79% vs octreotide LAR (Strosberg et al., 2017). CLARINET: lanreotide improved PFS (NR vs 18 months) in non-functional NETs (Caplin et al., 2014). Telotristat ethyl FDA approved 2017 — TELESTAR trial: reduced bowel movement frequency by 1.7/day vs placebo (Kulke et al., 2017). Niacin deficiency (pellagra) is a recognized complication of carcinoid syndrome due to tryptophan depletion (Feldman et al., 1981).
Core Nutrition Principles
- 1Carcinoid syndrome diarrhea causes severe malabsorption of fat, protein, and fat-soluble vitamins (A, D, E, K) — aggressive nutritional repletion is essential
- 2Serotonin excess depletes tryptophan (the niacin precursor) — niacin (vitamin B3) deficiency causes pellagra (dermatitis, diarrhea, dementia); niacin supplementation is critical in carcinoid syndrome
- 3Low-tyramine, low-tryptophan diet reduces serotonin precursor availability and may reduce carcinoid flushing and diarrhea — avoid aged cheeses, fermented foods, alcohol, and high-tryptophan foods during active carcinoid syndrome
- 4Octreotide and lanreotide cause fat malabsorption and gallstone formation — pancreatic enzyme replacement therapy (PERT) and ursodeoxycholic acid may be needed
- 5Everolimus (mTOR inhibitor) causes hyperglycemia and mucositis — low-glycemic diet, blood sugar monitoring, and glutamine supplementation are important
- 6PRRT (lutetium-177 dotatate) requires amino acid infusion (lysine + arginine) to protect kidneys from radiation — adequate protein intake and renal function monitoring are essential
- 7Small, frequent meals reduce carcinoid flushing and diarrhea triggered by large meals — 5–6 small meals/day is the standard dietary approach
- 8Vitamin D deficiency is extremely common in NET patients due to fat malabsorption and somatostatin analogue use — aggressive supplementation and monitoring are required
Priority Foods
- Small, frequent meals (5–6/day) — reduces carcinoid flushing and diarrhea triggered by large meals; most important dietary strategy for carcinoid syndrome management
- Low-fat, easily digestible proteins (chicken, turkey, eggs, white fish) — reduce fat malabsorption from octreotide; adequate protein for muscle preservation; easy to digest
- Cooked, peeled vegetables (carrots, zucchini, green beans, sweet potatoes) — low-fiber, easy to digest; reduce diarrhea; antioxidants; avoid raw vegetables during active diarrhea
- White rice, oatmeal, and plain pasta — low-fiber, low-fat carbohydrates; soothing for irritated gut; easy to digest during carcinoid diarrhea
- Banana and applesauce — potassium replacement for diarrhea-induced hypokalemia; pectin fiber soothes gut; easy to digest
- Bone broth — electrolytes (sodium, potassium); collagen for gut mucosal healing; easy to consume; hydration support
- Niacin-rich foods (chicken, turkey, tuna, peanuts — in moderation) — replace niacin depleted by serotonin excess; pellagra prevention
- Avocado — calorie-dense; healthy fats (MCT-like); potassium; anti-inflammatory; tolerated better than long-chain fats in malabsorption
- Ginger tea — reduces nausea from octreotide injections and chemotherapy; anti-inflammatory; soothing
- Probiotic-rich foods (kefir, yogurt — low-fat, plain) — restore gut microbiome disrupted by diarrhea and antibiotics; Lactobacillus support
- Fortified foods (vitamin D-fortified milk or plant milk, B12-fortified cereals) — replace fat-soluble vitamins lost to malabsorption
Core Supplements
- Niacin (vitamin B3) — 50–100mg daily as niacinamide (not nicotinic acid — avoid flushing); CRITICAL in carcinoid syndrome; serotonin excess depletes tryptophan/niacin; prevents pellagra (dermatitis, diarrhea, dementia)
- Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); fat malabsorption and octreotide cause severe deficiency; immune support; anti-tumor; target 60–80 ng/mL; monitor 25-OH-D levels
- Vitamin A (as beta-carotene) — 10,000–15,000 IU daily as beta-carotene; fat malabsorption depletes vitamin A; immune function; mucosal integrity; avoid preformed retinol excess
- Vitamin E (mixed tocopherols) — 400 IU daily; fat malabsorption depletes vitamin E; antioxidant; immune support
- Vitamin K2 (MK-7) — 200mcg daily; fat malabsorption depletes vitamin K; bone health; coagulation; take with D3
- Pancreatic enzyme replacement therapy (PERT — lipase/amylase/protease) — for octreotide/lanreotide-induced fat malabsorption; take with every meal and snack; dose based on fat content of meal
- Omega-3 EPA/DHA — 2–3g daily; anti-inflammatory; anti-tumor; reduce carcinoid-associated inflammation; take with PERT to improve absorption
- Magnesium glycinate — 400–600mg daily; diarrhea causes severe magnesium depletion; muscle function; sleep; blood sugar regulation during everolimus therapy
- Probiotics (50 billion CFU multi-strain) — restore gut microbiome; reduce diarrhea severity; Lactobacillus rhamnosus GG + Bifidobacterium longum; take away from octreotide injection timing
- Glutamine — 10–20g daily; gut mucosal integrity; reduces everolimus-induced mucositis; muscle preservation; anti-cachexia
- Zinc picolinate — 30mg daily; diarrhea depletes zinc; immune function; wound healing; taste recovery; antioxidant
- B-complex (activated) — B12 (methylcobalamin 1,000mcg), B6 (P5P 50mg), folate (5-MTHF 800mcg); malabsorption depletes B vitamins; energy metabolism; nerve function
Treatment Protocols
- Surgical resection — curative intent for localized NETs; debulking surgery for metastatic disease to reduce tumor burden and hormone secretion; liver resection or ablation for liver metastases
- Octreotide LAR (Sandostatin LAR) — long-acting somatostatin analogue; 20–30mg IM every 4 weeks; controls carcinoid syndrome symptoms and slows tumor growth; PROMID trial: improved time to progression from 6 to 14.3 months in midgut NETs
- Lanreotide (Somatuline Depot) — long-acting somatostatin analogue; 120mg SC every 4 weeks; CLARINET trial: improved PFS in non-functional GI and pNETs (NR vs 18 months)
- Lutetium-177 dotatate (Lutathera) — PRRT; FDA approved 2018; NETTER-1 trial: 79% reduction in disease progression or death vs octreotide LAR; requires somatostatin receptor scintigraphy (Ga-68 DOTATATE PET) to confirm receptor expression; amino acid infusion required for kidney protection
- NETTER-2 trial (2024) — lutetium-177 dotatate first-line for high-uptake G2/G3 NETs; improved PFS vs high-dose octreotide LAR; expanding PRRT to earlier lines of therapy
- Everolimus (Afinitor) — mTOR inhibitor; FDA approved for progressive pNETs (RADIANT-3: 11.0 vs 4.6-month PFS) and non-functional GI/lung NETs (RADIANT-4: 11.0 vs 3.9-month PFS)
- Sunitinib (Sutent) — VEGFR/PDGFR/KIT inhibitor; FDA approved for progressive pNETs; SUN1111 trial: 11.4 vs 5.5-month PFS
- Telotristat ethyl (Xermelo) — tryptophan hydroxylase inhibitor; FDA approved 2017 for carcinoid syndrome diarrhea inadequately controlled by somatostatin analogues; reduces serotonin synthesis; 250mg three times daily
- Cabozantinib — MET/VEGFR2/AXL inhibitor; CABINET trial showing activity in pNETs and extra-pancreatic NETs; emerging option for refractory disease
- Surufatinib — VEGFR/FGFR1/CSF1R inhibitor; showing activity in NETs in Chinese trials; under evaluation in Western populations
- Ga-68 DOTATATE PET/CT — most sensitive imaging for somatostatin receptor-expressing NETs; guides PRRT eligibility; superior to octreotide scintigraphy
- Chromogranin A (CgA) monitoring — primary tumor marker for NETs; 24-hour urine 5-HIAA for carcinoid syndrome; monitor every 3–6 months
- Carcinoid heart disease monitoring — echocardiogram every 1–2 years; serotonin causes tricuspid and pulmonary valve fibrosis; octreotide reduces serotonin and slows valve disease progression
- NETTER-2 trial (2024) — lutetium-177 dotatate first-line for high-uptake G2/G3 NETs: PFS 22.8 vs 8.5 months (HR 0.276) vs high-dose octreotide LAR; expanding PRRT to earlier lines and higher-grade NETs; changes first-line treatment paradigm for G2/G3 somatostatin receptor-positive NETs
- Cabozantinib (CABINET trial) — FDA approved 2024 for NETs; pNETs: 8.5-month PFS vs 3.2 months placebo; extra-pancreatic NETs: 5.6-month PFS vs 3.4 months; option after somatostatin analogues and PRRT
- Lutetium-177 dotatate + everolimus (COMPETE trial) — combination PRRT + mTOR inhibitor: 20.1-month PFS vs 12.0 months with everolimus alone; emerging combination approach for somatostatin receptor-positive NETs
- Surufatinib — VEGFR/FGFR1/CSF1R inhibitor; SANET-ep and SANET-p Phase III trials showing activity in extra-pancreatic and pancreatic NETs; NDA submitted to FDA; emerging option for refractory NETs
- Actinium-225 dotatate (alpha-PRRT) — alpha-emitter PRRT; more potent than lutetium-177 with shorter range (reduces off-target toxicity); Phase I/II trials showing activity in PRRT-refractory NETs; investigational
- Belzutifan (Welireg) — HIF-2alpha inhibitor; FDA approved 2021 for VHL disease-associated pNETs, hemangioblastomas, and RCC; oral once daily; for VHL syndrome patients with pNETs
- Selpercatinib (Retevmo) — RET inhibitor; for RET-mutant pNETs in MEN2 syndrome; FDA approved for RET-mutant thyroid cancer and NSCLC; tissue-agnostic activity in RET-altered tumors
- Comprehensive molecular profiling for pNETs — DAXX/ATRX (alternative lengthening of telomeres — poor prognosis), MEN1, VHL, RET, SDHB, TSC1/2; guides targeted therapy selection and clinical trial eligibility
- Oncology dietitian — essential for carcinoid syndrome dietary management, PERT dosing, and fat-soluble vitamin repletion
Foods & Substances to Avoid
- Carcinoid flush triggers — alcohol (especially red wine), aged cheeses, fermented foods, spicy foods, large meals, stress, and exercise can trigger carcinoid flushing and diarrhea; identify and avoid individual triggers
- High-tryptophan foods during active carcinoid syndrome (turkey, chicken in excess, eggs in excess, dairy in excess) — tryptophan is the serotonin precursor; moderate intake; telotristat ethyl reduces serotonin synthesis more effectively
- High-tyramine foods (aged cheeses, cured meats, fermented foods, soy sauce, red wine) — trigger carcinoid flushing; avoid during active carcinoid syndrome
- High-fat meals — worsen fat malabsorption from octreotide; trigger diarrhea; use PERT with all fat-containing meals; switch to low-fat diet with MCT oil supplementation
- Alcohol — triggers carcinoid flushing and diarrhea; hepatotoxic; interacts with everolimus and sunitinib metabolism; complete avoidance recommended
- Grapefruit with everolimus, sunitinib, or cabozantinib — CYP3A4 inhibition significantly increases drug levels and toxicity
- St. John's Wort — CYP3A4 inducer; reduces everolimus, sunitinib, and cabozantinib efficacy
- High-fiber raw foods during active diarrhea — worsen diarrhea and malabsorption; switch to low-fiber cooked foods; reintroduce fiber gradually when diarrhea is controlled
- Large meals — trigger carcinoid flushing and diarrhea; switch to 5–6 small meals/day
- NSAIDs (ibuprofen, naproxen) — interact with sunitinib and everolimus; worsen GI symptoms; use acetaminophen for pain
- Excess sugar and refined carbohydrates — worsen everolimus-induced hyperglycemia; promote insulin resistance
Get your personalized protocol
Take the full assessment to receive a protocol tailored to your specific symptoms and goals.
Start AssessmentKey Nutrients
Drug & Supplement Interactions
Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.
- •Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
- •Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
- •Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2
- •Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
- •Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR
- •Statins — combination increases risk of myopathy and rhabdomyolysis; use with caution
- •Blood pressure medications — additive vasodilatory effect; may cause flushing and hypotension
- •Diabetes medications — high-dose niacin may impair glucose control
- •Alcohol — increases flushing and liver stress
- •Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
- •Warfarin — high-dose vitamin A may increase anticoagulant effect
- •Orlistat — reduces fat-soluble vitamin absorption including vitamin A
- •Cholestyramine — reduces vitamin A absorption
- •Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
- •Phenytoin and phenobarbital — B6 may reduce drug levels
- •Statins — combination increases risk of myopathy; use with caution
- •Diabetes medications — high-dose niacin may impair glucose control
- •Blood pressure medications — additive vasodilatory effect
- •Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
- •Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
- •Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
- •Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
- •Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
- •Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses
- •Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
- •Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
- •Statins — may reduce statin effectiveness at very high doses
- •Cyclosporine — may reduce drug levels
- •Niacin — high-dose combination may reduce HDL-raising effect of niacin
- •Warfarin — high doses (>1g/day) may reduce anticoagulant effect
- •Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
- •Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
- •Statins — very high doses may reduce statin effectiveness
- •Aluminum antacids — vitamin C increases aluminum absorption; avoid combination
- •Metformin — long-term use depletes B12; supplementation is recommended
- •PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
- •Chloramphenicol — may reduce B12 effectiveness
- •Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
- •Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
- •Cyclosporine — may reduce drug levels; monitor in transplant patients
- •Antibiotics (tetracyclines, fluoroquinolones) — magnesium reduces absorption; separate by 2+ hours
- •Bisphosphonates (alendronate) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Diuretics — thiazide diuretics increase magnesium excretion; loop diuretics may deplete magnesium
- •Digoxin — magnesium deficiency increases digoxin toxicity risk; supplementation may be protective
- •Muscle relaxants — additive effect; may increase sedation
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Bisphosphonates — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Lactulose (for hepatic encephalopathy) — glutamine may worsen ammonia levels in liver disease
- •Anticonvulsants — glutamine may lower seizure threshold in some individuals
- •Chemotherapy — may interfere with some agents; consult oncologist
- •Antibiotics (tetracyclines, fluoroquinolones) — zinc reduces antibiotic absorption; separate by 2+ hours
- •Copper — high-dose zinc (>40mg/day) depletes copper; supplement 1–2mg copper per 30mg zinc
- •Iron supplements — compete for absorption; separate by 2+ hours
- •Penicillamine (for rheumatoid arthritis) — zinc reduces drug absorption
- •Thiazide diuretics — increase zinc excretion
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
- •Copper — high-dose zinc depletes copper
- •Immunosuppressants — use with caution; risk of infection in severely immunocompromised patients
- •Antibiotics — take probiotics 2+ hours away from antibiotics to preserve viability
- •Antifungals — may reduce probiotic viability
This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.
This protocol is for informational purposes only. Consult a qualified healthcare provider before making dietary or supplement changes.